多瑞医药
(301075)
| 流通市值：35.75亿 | | | 总市值：50.54亿 |
| 流通股本：5660.00万 | | | 总股本：8000.00万 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 95,655,393.08 | 32,431,205.53 | 154,176,460.28 | 136,998,003.2 |
| 营业总成本 | 137,708,660.18 | 54,224,700.54 | 274,302,230.06 | 244,884,906.84 |
| 其他经营收益 | | | | |
| 营业利润 | 4,713,818.49 | -18,842,206.09 | -128,374,071.67 | -110,317,312.85 |
| 利润总额 | 6,247,926.59 | -18,951,964.26 | -131,357,431.7 | -111,151,584.21 |
| 净利润 | 3,240,666.51 | -19,014,237.05 | -132,401,390.23 | -112,698,674.46 |
| 每股收益 | | | | |
| 其他综合收益 | 200,000 | - | - | - |
| 综合收益总额 | 3,440,666.51 | -19,014,237.05 | -132,401,390.23 | -112,698,674.46 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 322,042,231.19 | 329,537,715.22 | 329,063,783.83 | 560,246,039.98 |
| 非流动资产: | | | | |
| 非流动资产合计 | 988,127,476.98 | 998,127,031.99 | 954,150,274.46 | 887,103,160.19 |
| 资产总计 | 1,310,169,708.17 | 1,327,664,747.21 | 1,283,214,058.29 | 1,447,349,200.17 |
| 流动负债: | | | | |
| 流动负债合计 | 487,167,681.81 | 451,118,651 | 442,136,519.06 | 480,960,809.52 |
| 非流动负债: | | | | |
| 非流动负债合计 | 123,079,139.36 | 215,532,309.84 | 217,537,139.78 | 325,709,354.18 |
| 负债合计 | 610,246,821.17 | 666,650,960.84 | 659,673,658.84 | 806,670,163.7 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 659,565,510.15 | 617,031,129.65 | 574,511,474.73 | 596,907,743.04 |
| 股东权益合计 | 699,922,887 | 661,013,786.37 | 623,540,399.45 | 640,679,036.47 |
| 负债和股东权益合计 | 1,310,169,708.17 | 1,327,664,747.21 | 1,283,214,058.29 | 1,447,349,200.17 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 127,257,713.05 | 43,606,259.08 | 197,483,273.31 | 171,914,271.07 |
| 经营活动现金流出小计 | 171,691,667.14 | 80,258,766.48 | 243,315,701.9 | 206,640,300.54 |
| 经营活动产生的现金流量净额 | -44,433,954.09 | -36,652,507.4 | -45,832,428.59 | -34,726,029.47 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 98,475,965.6 | 25,553,298.07 | 1,187,736,685.45 | 1,066,312,713.91 |
| 投资活动现金流出小计 | 68,896,424.79 | 47,696,360.19 | 1,015,151,895.49 | 1,079,636,244.6 |
| 投资活动产生的现金流量净额 | 29,579,540.81 | -22,143,062.12 | 172,584,789.96 | -13,323,530.69 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 76,403,810.32 | 56,442,970.07 | 127,880,000 | 127,972,826 |
| 筹资活动现金流出小计 | 81,904,512.7 | 17,481,267.23 | 279,473,190.49 | 88,616,001.95 |
| 筹资活动产生的现金流量净额 | -5,500,702.38 | 38,961,702.84 | -151,593,190.49 | 39,356,824.05 |
| 汇率变动对现金及现金等价物的影响 | - | - | -1,462.29 | - |
| 现金及现金等价物净增加额 | -20,355,115.66 | -19,833,866.68 | -24,842,291.41 | -8,692,736.11 |
| 期末现金及现金等价物余额 | 64,920,914.84 | 65,444,163.82 | 85,276,030.5 | 253,435,579.28 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -20,355,115.66 | - | -24,842,291.41 | - |